Elevated plasma endoglin (CD105) predicts decreased response and survival in a
metastatic breast cancer trial of hormone therapy.
Author(s): Vo MN, Evans M, Leitzel K, Ali SM, Wilson M, Demers L, Evans DB, Lipton A.
Affiliation(s): Hershey Medical Center, Penn State University, Hershey, PA, USA.
Publication date & source: 2010, Breast Cancer Res Treat. , 119(3):767-71
Background Endoglin (CD105) is a co-receptor for TGF-beta, is expressed by human
vascular endothelial cells, and plays a major role in angiogenesis. Materials and
methods Pretreatment EDTA plasma from 224 metastatic breast cancer patients
enrolled in a phase III 2nd-line hormone therapy trial and 50 control subjects
were assayed for endoglin using an ELISA. Results The female control group (n =
50) plasma endoglin upper limit of normal was defined as the mean + 2 SD (8.7
ng/ml). The breast cancer patient plasma endoglin was 6.40 +/- 2.23 ng/ml (range
3.00-19.79 ng/ml). Elevated plasma endoglin levels were detected in 26 of 224
patients (11.6%). Patients with elevated plasma endoglin had a reduced clinical
benefit rate (CR + PR + Stable) (15 vs. 42%) (P = 0.01) to hormone therapy. TTP
was shorter for patients with elevated plasma endoglin, but did not reach
statistical significance (P = 0.2). Patients with elevated plasma endoglin had
decreased overall survival (median 645 vs. 947 days) (P = 0.005). Conclusion
Elevated pretreatment plasma endoglin levels predicted for decreased clinical
benefit and a shorter overall survival in metastatic breast cancer patients
treated with 2nd-line hormone therapy.
|